# GO	NS	enrichment	name	ratio_in_study	ratio_in_pop	p_uncorrected	depth	study_count	p_fdr_bh	study_items
hsa05418	XX	e	Fluid shear stress and atherosclerosis	15/93	139/8061	4.1076544161663847e-11	n.a	15	1.355525957334907e-08	ACTB, CCL2, GSTA4, GSTM1, GSTM3, HMOX1, IFNG, IL1B, MAP3K5, MMP2, MMP9, NFE2L2, NOS3, PLAT, VEGFA
hsa04933	XX	e	AGE-RAGE signaling pathway in diabetic complications	10/93	100/8061	1.885494943772868e-07	n.a	10	3.111066657225232e-05	AGT, BAX, CCL2, IL1B, IL6, MMP2, NOS3, NOX4, PRKCD, VEGFA
hsa04657	XX	e	IL-17 signaling pathway	8/93	94/8061	1.1442516435649068e-05	n.a	8	0.0012586768079213	CCL2, CSF3, CXCL10, IFNG, IL1B, IL6, LCN2, MMP9
hsa05022	XX	e	Pathways of neurodegeneration - multiple diseases	17/93	475/8061	2.4846829419639455e-05	n.a	17	0.0020498634271202	APP, BAX, CAT, ERN1, GPX1, HSPA5, HTT, IL1B, IL6, MAP3K5, MAPT, NOX4, PRKN, PSEN1, SNCA, TUBA1A, TUBB4B
hsa04066	XX	e	HIF-1 signaling pathway	8/93	109/8061	3.3911051493673435e-05	n.a	8	0.0022381293985824	ALDOB, ENO1, HMOX1, IFNG, IGF1, IL6, NOS3, VEGFA
hsa04211	XX	e	Longevity regulating pathway	7/93	89/8061	6.917522029198843e-05	n.a	7	0.0038046371160593	ADIPOQ, ATG5, BAX, CAT, IGF1, PPARG, SESN2
hsa04216	XX	e	Ferroptosis	5/93	41/8061	9.901228940317308e-05	n.a	5	0.004667722214721	ACSL1, ATG5, CP, HMOX1, MAP1LC3B
hsa03320	XX	e	PPAR signaling pathway	6/93	74/8061	0.0001976398352825	n.a	6	0.0081526432054047	ACSL1, ADIPOQ, APOA1, ME1, PPARA, PPARG
hsa00980	XX	e	Metabolism of xenobiotics by cytochrome P450	6/93	76/8061	0.0002289706792611	n.a	6	0.0083955915729084	CYP2C9, CYP2E1, EPHX1, GSTA4, GSTM1, GSTM3
hsa05144	XX	e	Malaria	5/93	50/8061	0.0002579628036535	n.a	5	0.0084374766512653	CCL2, CSF3, IFNG, IL1B, IL6
hsa04668	XX	e	TNF signaling pathway	7/93	112/8061	0.000293407478748	n.a	7	0.0084374766512653	CCL2, CXCL10, IL1B, IL6, MAP3K5, MMP9, RIPK3
hsa04932	XX	e	Non-alcoholic fatty liver disease	8/93	150/8061	0.0003191625419054	n.a	8	0.0084374766512653	ADIPOQ, BAX, CYP2E1, ERN1, IL1B, IL6, MAP3K5, PPARA
hsa05200	XX	e	Pathways in cancer	16/93	531/8061	0.0003323854438377	n.a	16	0.0084374766512653	AGT, BAX, GSTA4, GSTM1, GSTM3, HMOX1, IFNA2, IFNG, IGF1, IL6, MMP2, MMP9, NFE2L2, NOTCH1, PPARG, VEGFA
hsa05204	XX	e	Chemical carcinogenesis	6/93	83/8061	0.0003705827846404	n.a	6	0.0087351656379541	CYP2C9, CYP2E1, EPHX1, GSTA4, GSTM1, GSTM3
hsa04217	XX	e	Necroptosis	8/93	159/8061	0.0004725985257168	n.a	8	0.0103971675657696	AIFM1, BAX, HMGB1, IFNA2, IFNG, IL1B, PYGL, RIPK3
hsa05012	XX	e	Parkinson disease	10/93	249/8061	0.0005601551438762	n.a	10	0.0108735998517163	BAX, ERN1, HSPA5, MAP3K5, MAPT, NFE2L2, PRKN, SNCA, TUBA1A, TUBB4B
hsa05132	XX	e	Salmonella infection	10/93	249/8061	0.0005601551438762	n.a	10	0.0108735998517163	ACTB, ACTR3, ANXA2, BAX, IL1B, IL6, IRAK1, RIPK3, TUBA1A, TUBB4B
hsa04623	XX	e	Cytosolic DNA-sensing pathway	5/93	63/8061	0.0007606508914014	n.a	5	0.0135207488969525	CXCL10, IFNA2, IL1B, IL6, RIPK3
hsa05164	XX	e	Influenza A	8/93	172/8061	0.0007952572135697	n.a	8	0.0135207488969525	ACTB, BAX, CCL2, CXCL10, IFNA2, IFNG, IL1B, IL6
hsa05143	XX	e	African trypanosomiasis	4/93	37/8061	0.000819439327088	n.a	4	0.0135207488969525	APOA1, IFNG, IL1B, IL6
hsa05010	XX	e	Alzheimer disease	12/93	369/8061	0.0010301073212197	n.a	12	0.0161874007620252	APOE, APP, ERN1, IL1B, IL6, MAP3K5, MAPT, NOX4, PSEN1, SNCA, TUBA1A, TUBB4B
hsa04620	XX	e	Toll-like receptor signaling pathway	6/93	104/8061	0.0012276726744357	n.a	6	0.0176392108855598	CXCL10, IFNA2, IL1B, IL6, IRAK1, SPP1
hsa00982	XX	e	Drug metabolism - cytochrome P450	5/93	70/8061	0.0012293995465693	n.a	5	0.0176392108855598	CYP2C9, CYP2E1, GSTA4, GSTM1, GSTM3
hsa05171	XX	e	Coronavirus disease - COVID-19	9/93	232/8061	0.0013640062674461	n.a	9	0.018755086177385	CCL2, CSF3, CXCL10, FGA, IFNA2, IL1B, IL6, IRAK1, VWF
hsa04931	XX	e	Insulin resistance	6/93	108/8061	0.0014922682635322	n.a	6	0.0196979410786262	AGT, IL6, NOS3, PPARA, PRKCD, PYGL
hsa04918	XX	e	Thyroid hormone synthesis	5/93	75/8061	0.001675731469225	n.a	5	0.0212688994170875	ALB, CANX, GPX1, HSPA5, TTR
hsa05130	XX	e	Pathogenic Escherichia coli infection	8/93	197/8061	0.0019029168480923	n.a	8	0.0232578725877956	ACTB, ACTR3, BAX, IL1B, IL6, IRAK1, TUBA1A, TUBB4B
hsa00983	XX	e	Drug metabolism - other enzymes	5/93	80/8061	0.0022310703197006	n.a	5	0.0262947573393296	CYP2E1, GSTA4, GSTM1, GSTM3, NME2
hsa05225	XX	e	Hepatocellular carcinoma	7/93	168/8061	0.0031750749178686	n.a	7	0.0361301628585057	ACTB, BAX, GSTA4, GSTM1, GSTM3, HMOX1, NFE2L2
hsa04141	XX	e	Protein processing in endoplasmic reticulum	7/93	171/8061	0.0035030251615876	n.a	7	0.0385332767774642	BAX, CANX, ERN1, HSPA5, MAP3K5, NFE2L2, PRKN
hsa00480	XX	e	Glutathione metabolism	4/93	57/8061	0.0041127489109889	n.a	4	0.0437808755040757	GPX1, GSTA4, GSTM1, GSTM3
hsa05323	XX	e	Rheumatoid arthritis	5/93	93/8061	0.0042901952310824	n.a	5	0.0442426383205377	CCL2, IFNG, IL1B, IL6, VEGFA
hsa04210	XX	e	Apoptosis	6/93	136/8061	0.0047394552539479	n.a	6	0.0450205950993681	ACTB, AIFM1, BAX, ERN1, MAP3K5, TUBA1A
hsa04621	XX	e	NOD-like receptor signaling pathway	7/93	181/8061	0.0047857358680968	n.a	7	0.0450205950993681	ATG5, CCL2, IFNA2, IL1B, IL6, PRKCD, RIPK3
hsa00030	XX	e	Pentose phosphate pathway	3/93	30/8061	0.0048173213679212	n.a	3	0.0450205950993681	ALDOB, RGN, TALDO1
hsa05135	XX	e	Yersinia infection	6/93	137/8061	0.0049113376472037	n.a	6	0.0450205950993681	ACTB, ACTR3, CCL2, IL1B, IL6, IRAK1
hsa05142	XX	e	Chagas disease	5/93	102/8061	0.0063413990536169	n.a	5	0.0565584239917185	CCL2, IFNG, IL1B, IL6, IRAK1
hsa05014	XX	e	Amyotrophic lateral sclerosis	10/93	364/8061	0.0089313096381313	n.a	10	0.0775613731732458	ACTB, BAX, CAT, ERN1, GPX1, HSPA5, MAP3K5, PRKN, TUBA1A, TUBB4B
hsa05219	XX	e	Bladder cancer	3/93	41/8061	0.0115471954926056	n.a	3	0.0952643628139964	MMP2, MMP9, VEGFA
hsa04722	XX	e	Neurotrophin signaling pathway	5/93	119/8061	0.0119402105016564	n.a	5	0.0961041333060154	BAX, IRAK1, MAP3K5, PRKCD, PSEN1
hsa05332	XX	e	Graft-versus-host disease	3/93	42/8061	0.012333206790031	n.a	3	0.0969037676359584	IFNG, IL1B, IL6
hsa05020	XX	e	Prion disease	8/93	273/8061	0.0132460477189111	n.a	8	0.1016557150521091	BAX, HSPA5, IL1B, IL6, NOTCH1, PRKCD, TUBA1A, TUBB4B
hsa04610	XX	e	Complement and coagulation cascades	4/93	85/8061	0.0165241360593691	n.a	4	0.1225899816517028	CFH, FGA, PLAT, VWF
hsa00620	XX	e	Pyruvate metabolism	3/93	47/8061	0.0167168156797776	n.a	3	0.1225899816517028	DLAT, ME1, PC
hsa05152	XX	e	Tuberculosis	6/93	180/8061	0.0175267979310421	n.a	6	0.1254553829331057	BAX, IFNA2, IFNG, IL1B, IL6, IRAK1
hsa00061	XX	e	Fatty acid biosynthesis	2/93	18/8061	0.0178678878722908	n.a	2	0.1254553829331057	ACSL1, FASN
hsa00330	XX	e	Arginine and proline metabolism	3/93	50/8061	0.0197141051807398	n.a	3	0.1283271478302571	ARG1, CKB, NOS3
hsa04979	XX	e	Cholesterol metabolism	3/93	50/8061	0.0197141051807398	n.a	3	0.1283271478302571	APOA1, APOE, APOH
hsa04976	XX	e	Bile secretion	4/93	90/8061	0.0199701042597283	n.a	4	0.1283271478302571	ABCB1, ABCC2, EPHX1, NR1H4
hsa05410	XX	e	Hypertrophic cardiomyopathy	4/93	90/8061	0.0199701042597283	n.a	4	0.1283271478302571	ACTB, AGT, IGF1, IL6
hsa04060	XX	e	Cytokine-cytokine receptor interaction	8/93	295/8061	0.0202212475368889	n.a	8	0.1283271478302571	CCL2, CCR2, CSF3, CXCL10, IFNA2, IFNG, IL1B, IL6
hsa00670	XX	e	One carbon pool by folate	2/93	20/8061	0.0218608269548693	n.a	2	0.134386926975139	DHFR, MTHFR
hsa05162	XX	e	Measles	5/93	139/8061	0.0219905880504772	n.a	5	0.134386926975139	BAX, IFNA2, IL1B, IL6, IRAK1
hsa05202	XX	e	Transcriptional misregulation in cancer	6/93	192/8061	0.0232725160630687	n.a	6	0.1396350963784125	BAX, IGF1, IL6, MMP9, PLAT, PPARG
hsa05016	XX	e	Huntington disease	8/93	306/8061	0.0245535437004809	n.a	8	0.1446905253778339	BAX, ERN1, GPX1, HTT, MAP3K5, PPARG, TUBA1A, TUBB4B
hsa00220	XX	e	Arginine biosynthesis	2/93	22/8061	0.026185920006232	n.a	2	0.1516026947729223	ARG1, NOS3
hsa04061	XX	e	Viral protein interaction with cytokine and cytokine receptor	4/93	100/8061	0.0281135162193256	n.a	4	0.1599562129720252	CCL2, CCR2, CXCL10, IL6
hsa05146	XX	e	Amoebiasis	4/93	102/8061	0.0299476461722014	n.a	4	0.167503783675025	ARG1, IFNG, IL1B, IL6
hsa00590	XX	e	Arachidonic acid metabolism	3/93	61/8061	0.0330797122253122	n.a	3	0.1819384172392171	CYP2C9, CYP2E1, GPX1
hsa04213	XX	e	Longevity regulating pathway - multiple species	3/93	62/8061	0.0344790195989431	n.a	3	0.1824843414809045	ATG5, CAT, IGF1
hsa05160	XX	e	Hepatitis C	5/93	157/8061	0.0347466625275633	n.a	5	0.1824843414809045	BAX, CXCL10, IFNA2, IFNG, PPARA
hsa04659	XX	e	Th17 cell differentiation	4/93	107/8061	0.0348379197372635	n.a	4	0.1824843414809045	AHR, IFNG, IL1B, IL6
hsa05321	XX	e	Inflammatory bowel disease	3/93	65/8061	0.0388587186796797	n.a	3	0.1978066632650346	IFNG, IL1B, IL6
hsa05161	XX	e	Hepatitis B	5/93	162/8061	0.0389619185219007	n.a	5	0.1978066632650346	BAX, IFNA2, IL6, IRAK1, MMP9
hsa00010	XX	e	Glycolysis / Gluconeogenesis	3/93	67/8061	0.0419287258695119	n.a	3	0.2096436293475596	ALDOB, DLAT, ENO1
hsa00591	XX	e	Linoleic acid metabolism	2/93	29/8061	0.0436993057502201	n.a	2	0.2152353865309351	CYP2C9, CYP2E1
hsa04920	XX	e	Adipocytokine signaling pathway	3/93	69/8061	0.0451175383665649	n.a	3	0.2163926373286613	ACSL1, ADIPOQ, PPARA
hsa05163	XX	e	Human cytomegalovirus infection	6/93	225/8061	0.0452457332596291	n.a	6	0.2163926373286613	BAX, CCL2, IFNA2, IL1B, IL6, VEGFA
hsa00020	XX	e	Citrate cycle (TCA cycle)	2/93	30/8061	0.0464765903495584	n.a	2	0.21731703152778	DLAT, PC
hsa04622	XX	e	RIG-I-like receptor signaling pathway	3/93	70/8061	0.0467560886014314	n.a	3	0.21731703152778	ATG5, CXCL10, IFNA2
hsa04152	XX	e	AMPK signaling pathway	4/93	120/8061	0.0496102311916094	n.a	4	0.2273802262948766	ADIPOQ, FASN, IGF1, PPARG
hsa04115	XX	e	p53 signaling pathway	3/93	73/8061	0.0518461640445331	n.a	3	0.2343730703383006	BAX, IGF1, SESN2
hsa04611	XX	e	Platelet activation	4/93	124/8061	0.054753917163097	n.a	4	0.2427945731774075	ACTB, FGA, NOS3, VWF
hsa00051	XX	e	Fructose and mannose metabolism	2/93	33/8061	0.0551805848130471	n.a	2	0.2427945731774075	ALDOB, SORD
hsa05133	XX	e	Pertussis	3/93	76/8061	0.0571937620120704	n.a	3	0.248341335052411	IL1B, IL6, IRAK1
hsa05140	XX	e	Leishmaniasis	3/93	77/8061	0.059032543500341	n.a	3	0.2529966150014614	IFNG, IL1B, IRAK1
hsa04612	XX	e	Antigen processing and presentation	3/93	78/8061	0.0608990786761554	n.a	3	0.2572156716147872	CANX, HSPA5, IFNG
hsa04926	XX	e	Relaxin signaling pathway	4/93	129/8061	0.0615758729017218	n.a	4	0.2572156716147872	MMP2, MMP9, NOS3, VEGFA
hsa05131	XX	e	Shigellosis	6/93	246/8061	0.0643548312228781	n.a	6	0.2654636787943723	ACTB, ACTR3, ATG5, BAX, IL1B, PRKCD
hsa04151	XX	e	PI3K-Akt signaling pathway	8/93	354/8061	0.0661168900904572	n.a	8	0.2687287980075709	CSF3, IFNA2, IGF1, IL6, NOS3, SPP1, VEGFA, VWF
hsa05216	XX	e	Thyroid cancer	2/93	37/8061	0.0675893643473587	n.a	2	0.2687287980075709	BAX, PPARG
hsa04146	XX	e	Peroxisome	3/93	82/8061	0.0686380467263998	n.a	3	0.2696494692822853	ACSL1, CAT, HACL1
hsa04915	XX	e	Estrogen signaling pathway	4/93	137/8061	0.0733841982356056	n.a	4	0.2815905281133703	MMP2, MMP9, NOS3, PRKCD
hsa04140	XX	e	Autophagy - animal	4/93	137/8061	0.0733841982356056	n.a	4	0.2815905281133703	ATG5, ERN1, HMGB1, PRKCD
hsa04510	XX	e	Focal adhesion	5/93	201/8061	0.0822931898891818	n.a	5	0.308895294293411	ACTB, IGF1, SPP1, VEGFA, VWF
hsa05169	XX	e	Epstein-Barr virus infection	5/93	202/8061	0.0836473499573796	n.a	5	0.308895294293411	BAX, CXCL10, IFNA2, IL6, IRAK1
hsa00380	XX	e	Tryptophan metabolism	2/93	42/8061	0.0842441711709302	n.a	2	0.308895294293411	CAT, HADHA
hsa00860	XX	e	Porphyrin and chlorophyll metabolism	2/93	42/8061	0.0842441711709302	n.a	2	0.308895294293411	CP, HMOX1
hsa04940	XX	e	Type I diabetes mellitus	2/93	43/8061	0.0877122158183061	n.a	2	0.3114810189101032	IFNG, IL1B
hsa00071	XX	e	Fatty acid degradation	2/93	43/8061	0.0877122158183061	n.a	2	0.3114810189101032	ACSL1, HADHA
hsa05205	XX	e	Proteoglycans in cancer	5/93	205/8061	0.0877810144201199	n.a	5	0.3114810189101032	ACTB, IGF1, MMP2, MMP9, VEGFA
hsa02010	XX	e	ABC transporters	2/93	45/8061	0.094773718387629	n.a	2	0.3327162454033785	ABCB1, ABCC2
hsa04930	XX	e	Type II diabetes mellitus	2/93	46/8061	0.0983643798159564	n.a	2	0.3366516018614963	ADIPOQ, PRKCD
hsa04145	XX	e	Phagosome	4/93	152/8061	0.0983776322843726	n.a	4	0.3366516018614963	ACTB, CANX, TUBA1A, TUBB4B
hsa05414	XX	e	Dilated cardiomyopathy	3/93	96/8061	0.0989551678198943	n.a	3	0.3366516018614963	ACTB, AGT, IGF1
hsa04666	XX	e	Fc gamma R-mediated phagocytosis	3/93	97/8061	0.101299741883334	n.a	3	0.3376658062777801	ACTR3, GSN, PRKCD
hsa05215	XX	e	Prostate cancer	3/93	97/8061	0.101299741883334	n.a	3	0.3376658062777801	IGF1, MMP9, PLAT
hsa04750	XX	e	Inflammatory mediator regulation of TRP channels	3/93	98/8061	0.1036666219073119	n.a	3	0.3420998522941295	IGF1, IL1B, PRKCD
hsa04640	XX	e	Hematopoietic cell lineage	3/93	99/8061	0.1060555034922753	n.a	3	0.3458921046861806	CSF3, IL1B, IL6
hsa05165	XX	e	Human papillomavirus infection	7/93	331/8061	0.1069121050848194	n.a	7	0.3458921046861806	BAX, IFNA2, NOTCH1, PSEN1, SPP1, VEGFA, VWF
hsa04630	XX	e	JAK-STAT signaling pathway	4/93	162/8061	0.11698159228709	n.a	4	0.3747953927644634	CSF3, IFNA2, IFNG, IL6
hsa04625	XX	e	C-type lectin receptor signaling pathway	3/93	104/8061	0.118319161383736	n.a	3	0.3754358005445471	IL1B, IL6, PRKCD
hsa04530	XX	e	Tight junction	4/93	169/8061	0.1308579466149227	n.a	4	0.4112678322183286	ACTB, ACTR3, MAP3K5, TUBA1A
hsa00240	XX	e	Pyrimidine metabolism	2/93	57/8061	0.1400962269923291	n.a	2	0.4281546788774855	NME2, PNP
hsa05134	XX	e	Legionellosis	2/93	57/8061	0.1400962269923291	n.a	2	0.4281546788774855	IL1B, IL6
hsa04670	XX	e	Leukocyte transendothelial migration	3/93	114/8061	0.1443175218662984	n.a	3	0.4369246074851238	ACTB, MMP2, MMP9
hsa04330	XX	e	Notch signaling pathway	2/93	59/8061	0.1480507142825055	n.a	2	0.4401507721912328	NOTCH1, PSEN1
hsa04370	XX	e	VEGF signaling pathway	2/93	59/8061	0.1480507142825055	n.a	2	0.4401507721912328	NOS3, VEGFA
hsa04010	XX	e	MAPK signaling pathway	6/93	294/8061	0.1543864235508725	n.a	6	0.4548885693909636	IGF1, IL1B, IRAK1, MAP3K5, MAPT, VEGFA
hsa04071	XX	e	Sphingolipid signaling pathway	3/93	119/8061	0.1579730659379137	n.a	3	0.4613372722080666	BAX, MAP3K5, NOS3
hsa04380	XX	e	Osteoclast differentiation	3/93	127/8061	0.18060565234963	n.a	3	0.5228058357489291	IFNG, IL1B, PPARG
hsa04137	XX	e	Mitophagy - animal	2/93	68/8061	0.1848507225016209	n.a	2	0.5304412037003035	ATG5, PRKN
hsa04068	XX	e	FoxO signaling pathway	3/93	131/8061	0.1922409893842434	n.a	3	0.5422181751863275	CAT, IGF1, IL6
hsa05218	XX	e	Melanoma	2/93	72/8061	0.2016108000299314	n.a	2	0.5638268136430284	BAX, IGF1
hsa04371	XX	e	Apelin signaling pathway	3/93	137/8061	0.2100373557370222	n.a	3	0.5824565327161122	NOS3, PLAT, SPP1
hsa05214	XX	e	Glioma	2/93	75/8061	0.2142957854703061	n.a	2	0.5893134100433418	BAX, IGF1
hsa05212	XX	e	Pancreatic cancer	2/93	76/8061	0.2185417861089797	n.a	2	0.5960230530244903	BAX, VEGFA
hsa05100	XX	e	Bacterial invasion of epithelial cells	2/93	77/8061	0.2227953659070459	n.a	2	0.602643202863321	ACTB, ACTR3
hsa05224	XX	e	Breast cancer	3/93	147/8061	0.2404545016503837	n.a	3	0.6347998843570132	BAX, IGF1, NOTCH1
hsa04540	XX	e	Gap junction	2/93	88/8061	0.2698868439403514	n.a	2	0.6798676221398167	TUBA1A, TUBB4B
hsa04512	XX	e	ECM-receptor interaction	2/93	88/8061	0.2698868439403514	n.a	2	0.6798676221398167	SPP1, VWF
hsa04062	XX	e	Chemokine signaling pathway	4/93	192/8061	0.2856743149981624	n.a	4	0.6842470025015956	CCL2, CCR2, CXCL10, PRKCD
hsa05167	XX	e	Kaposi sarcoma-associated herpesvirus infection	4/93	193/8061	0.2867397048228205	n.a	4	0.6842470025015956	BAX, IFNA2, IL6, VEGFA
hsa04658	XX	e	Th1 and Th2 cell differentiation	2/93	92/8061	0.2870472692007173	n.a	2	0.6842470025015956	IFNG, NOTCH1
hsa04912	XX	e	GnRH signaling pathway	2/93	93/8061	0.2913327411627573	n.a	2	0.6842470025015956	MMP2, PRKCD
hsa04064	XX	e	NF-kappa B signaling pathway	2/93	104/8061	0.3381777607328358	n.a	2	0.7489843022942001	IL1B, IRAK1
hsa04714	XX	e	Thermogenesis	4/93	232/8061	0.3443392899634416	n.a	4	0.7525295740922897	ACSL1, ACTB, MAP3K5, PPARG
hsa04922	XX	e	Glucagon signaling pathway	2/93	107/8061	0.3508137487347779	n.a	2	0.7566571051142268	PPARA, PYGL
hsa05145	XX	e	Toxoplasmosis	2/93	112/8061	0.3716914460625368	n.a	2	0.787745633770743	IFNG, IRAK1
hsa04726	XX	e	Serotonergic synapse	2/93	113/8061	0.3758365881293601	n.a	2	0.7899749941572538	APP, CYP2C9
hsa05206	XX	e	MicroRNAs in cancer	5/93	310/8061	0.4084824851655189	n.a	5	0.8384594012458159	ABCB1, HMOX1, MMP9, NOTCH1, VEGFA
hsa05168	XX	e	Herpes simplex virus 1 infection	7/93	498/8061	0.5162720650939754	n.a	7	0.9561729039605508	BAX, CCL2, IFNA2, IFNG, IL1B, IL6, IRAK1
hsa04919	XX	e	Thyroid hormone signaling pathway	2/93	121/8061	0.6515770966745892	n.a	2	1.0	ACTB, NOTCH1
hsa00230	XX	e	Purine metabolism	2/93	129/8061	0.6616228673946113	n.a	2	1.0	NME2, PNP
hsa04650	XX	e	Natural killer cell mediated cytotoxicity	2/93	131/8061	0.6643020702352035	n.a	2	1.0	IFNA2, IFNG
hsa04270	XX	e	Vascular smooth muscle contraction	2/93	133/8061	0.6670396579331658	n.a	2	1.0	AGT, PRKCD
hsa04910	XX	e	Insulin signaling pathway	2/93	137/8061	0.67267383780399	n.a	2	1.0	FASN, PYGL
hsa05017	XX	e	Spinocerebellar ataxia	2/93	143/8061	0.6814659974060014	n.a	2	1.0	ERN1, MAP3K5
hsa05226	XX	e	Gastric cancer	2/93	149/8061	0.6905842401543342	n.a	2	1.0	ABCB1, BAX
hsa04921	XX	e	Oxytocin signaling pathway	2/93	154/8061	0.6983712078862319	n.a	2	1.0	ACTB, NOS3
hsa04150	XX	e	mTOR signaling pathway	2/93	154/8061	0.6983712078862319	n.a	2	1.0	IGF1, SESN2
hsa04934	XX	e	Cushing syndrome	2/93	155/8061	0.6999448979138456	n.a	2	1.0	AGT, AHR
hsa04015	XX	e	Rap1 signaling pathway	3/93	210/8061	0.7360151895490914	n.a	3	1.0	ACTB, IGF1, VEGFA
hsa05170	XX	e	Human immunodeficiency virus 1 infection	3/93	212/8061	0.7371520992010088	n.a	3	1.0	BAX, IFNA2, IRAK1
hsa04810	XX	e	Regulation of actin cytoskeleton	3/93	218/8061	0.7408176870043663	n.a	3	1.0	ACTB, ACTR3, GSN
hsa05166	XX	e	Human T-cell leukemia virus 1 infection	3/93	219/8061	0.7414638416018515	n.a	3	1.0	BAX, CANX, IL6
hsa05203	XX	p	Viral carcinogenesis	2/93	203/8061	1.0	n.a	2	1.0	BAX, GSN
hsa04014	XX	p	Ras signaling pathway	2/93	232/8061	1.0	n.a	2	1.0	IGF1, VEGFA
hsa04020	XX	p	Calcium signaling pathway	2/93	240/8061	1.0	n.a	2	1.0	NOS3, VEGFA